Mithra, a company dedicated to Women’s Health, announces it has entered into a license and supply agreement with Spirig Healthcare AG for the commercialization of its tibolone-based product Tibelia® in Liechtenstein and Switzerland.
Developed by Mithra as the bioequivalent version of Livial®, Tibelia® is a complex oral formulation composed of tibolone, a synthetic steroid for use in hormone therapy. Tibolone relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at high risk of future fractures who are intolerant to other medicinal products. To date, Tibelia® is marketed in about 30 countries through existing license and supply agreements.
Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein and Switzerland, which has a tibolone market worth approximately EUR 1.5 million per year. Spirig HealthCare AG is a Swiss pharmaceutical company, subsidiary of the German group STADA Arzneimittel AG. It produces, markets and distributes more than 150 products, both high-quality generics and brands, to various healthcare professionals.
François Fornieri, CEO Mithra Women’s Health, commented: “We are pleased to have formed a partnership with Spirig Healthcare for the commercialization of Tibelia® in Switzerland and Liechtenstein. With their large network and extensive services to doctors and pharmacists, they are the ideal partner to market our product in this region. This agreement is part of our strategy to continue to maximize the potential of our product around the world.”
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. Its three lead development candidates are built on Mithra’s unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com